Docs at a personal hospital have reported a case of long-term survival in a affected person with HER2-positive metastatic gastric adenocarcinoma, illustrating {that a} personalised multidisciplinary method can obtain prolonged illness management in superior gastric most cancers.
The 65-year-old man offered in 2018 with belly ache, vomiting, important weight reduction, and metastatic liver involvement. Diagnostic analysis confirmed HER2-positive metastatic gastric adenocarcinoma, a extremely aggressive abdomen most cancers with a traditionally poor prognosis and fewer than 10% five-year survival fee for metastatic circumstances.
Keep linked
Make The Information Mill your most well-liked supply
See extra TNM tales if you seek for information on Google.
The affected person started first-line remedy with CAPOX chemotherapy (capecitabine and oxaliplatin) mixed with trastuzumab, a focused anti-HER2 remedy. This routine led to a considerable discount within the main tumour and liver metastases, permitting transition to long-term upkeep remedy.
After sustained illness management, a multidisciplinary crew carried out conversion surgical procedure to take away the first abdomen tumour following a superb systemic response. Subsequent imaging confirmed full disappearance of liver lesions.
Between 2021 and 2024, the affected person skilled two remoted recurrences of illness. As an alternative of altering systemic remedy, the crew addressed these with focused native therapies: precision radiotherapy for the recurrence close to the surgical web site and microwave ablation for a solitary liver lesion. HER2-targeted remedy was maintained all through, serving to maintain illness management and high quality of life.
Dr Shyam Aggarwal, Chairman of Medical Oncology at Sir Ganga Ram Hospital, commented, “Systemic remedy of gastric most cancers has advanced considerably over time. At this time, 4 key biomarkers–HER2, MSI, CPS, and Claudin 18.2–play an important position in figuring out essentially the most applicable first-line remedy technique. The addition of focused therapies alongside chemotherapy has remodeled outcomes for a lot of sufferers with abdomen most cancers. This case highlights how precision drugs and a personalised, multidisciplinary method will help obtain long-term illness management, even in sufferers with superior metastatic illness.”
Roughly 15-20% of gastric cancers overexpress the HER2 protein, allowing use of focused therapies resembling trastuzumab. Advances in molecular diagnostics, imaging, and multidisciplinary care enable clinicians to tailor therapies for chosen superior circumstances.
This case demonstrates that persevering with HER2-directed remedy mixed with fastidiously timed native interventions for remoted recurrences can provide sturdy medical profit past conventional expectations in metastatic gastric most cancers.
The docs emphasise that this case underscores the significance of precision oncology and individualised remedy planning, offering renewed hope for sufferers with superior HER2-positive gastric most cancers.
